Hepatitis A Vaccine (DB10989): A Comprehensive Monograph on a Foundational Public Health Intervention

Executive Summary

The Hepatitis A Vaccine (DrugBank ID: DB10989) represents a pivotal achievement in modern biotechnology and public health, offering robust protection against infection by the Hepatitis A virus (HAV). Classified as an inactivated viral vaccine, this biotech product is engineered to elicit a potent and durable immune response without posing a risk of causing the disease it is designed to prevent.[1] Clinical evidence has consistently demonstrated its high efficacy, preventing approximately 95% of clinical cases in vaccinated individuals.[1] The vaccine is highly immunogenic, inducing protective antibody levels in the vast majority of recipients after the first dose and approaching 100% seroprotection following the standard two-dose series.

The immunity conferred is remarkably long-lasting, with studies and mathematical models projecting protection for at least 30 to 40 years, and potentially for the recipient's entire life, obviating the need for routine booster doses after completion of the primary series.[1] This exceptional durability distinguishes it as one of the most effective long-term immunizations available. Furthermore, the vaccine possesses an outstanding safety profile, confirmed by decades of post-marketing surveillance involving tens of millions of doses. The most common adverse events are mild, transient, and localized to the injection site, with severe reactions being exceedingly rare.[1]